Xiao-ai-ping injection adjunct with platinum-based chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis

Fanchao Feng1,2†, Jingyi Huang1†, Zhichao Wang1†, Jiarui Zhang3, Di Han1, Qi Wu4, Hailang He1,2* and Xianmei Zhou1,2*

Abstract

Background: Xiao-ai-ping injection (XAPI), as patented Chinese medicine, has shown promising outcomes in non-small-cell lung cancer (NSCLC) patients. This meta-analysis investigated the efficacy and safety of XAPI in combination with platinum-based chemotherapy.

Methods: A comprehensive literature search was conducted to identify relevant studies in Pubmed, EMBASE, the Cochrane Library, Chinese National Knowledge Infrastructure, Wangfang Database, VIP Database, and Chinese Biology Medical Database from the date of their inception to September 2018. The RevMan 5.3 software was applied to calculate the risk ratio (RR) and mean difference (MD) with 95% confidence interval (CI).

Results: We included and analyzed 24 randomized controlled trials. The meta-analysis showed that XAPI adjunctive to platinum-based chemotherapy had better outcomes in objective tumor response rate (ORR) (RR: 1.27, 95% CI, 1.14–1.40); improved Karnofsky performance scores (KPS) (RR: 1.70, 95% CI, 1.48–1.95); reduction in occurrence of grade 3/4 leukopenia (RR: 0.49, 95% CI, 0.38–0.64), anemia (RR: 0.63, 95% CI, 0.46–0.87) and thrombocytopenia (RR: 0.53, 95% CI, 0.38–0.73), nausea and vomiting (RR: 0.57, 95% CI, 0.36–0.90); and enhanced immune function (CD8+ [MD: 4.96, 95% CI, 1.16–8.76] and CD4+/CD8+ [MD: 2.58, 95% CI, 1.69–3.47]). However, it did not increase dysregulated liver and kidney function, diarrhea, constipation, and fatigue. Subgroup analysis of ORR and KPS revealed that dosage, treatment duration, and methodological quality did not affect the outcome significantly.

Conclusions: Our meta-analyses demonstrated that XAPI in combination with platinum-based chemotherapy had a better tumor response, improved the quality of life, attenuated adverse side effects, and enhanced immune function, which suggests that it might be used for advanced NSCLC. Moreover, low dosage (< 60 ml/d) and long-term treatment of XAPI might be a choice for advanced NSCLC patients.

Keywords: Xiao-ai-ping injection, Platinum-based chemotherapy, Advanced non-small cell lung cancer, Objective tumor response, Adverse side effects, Meta-analysis
Background
Lung cancer is becoming a health burden in recent years, despite some advances in treatment in the past few decades [1]. It remains one of the leading causes of cancer-related death worldwide, with approximately 1.8 million new lung cancer cases and 1.6 million deaths per year [2]. Non-small-cell lung cancer (NSCLC) is the common subgroup, which accounts for approximately 85% of lung cancer cases [3] and most NSCLC patients present with advanced-stage, unresectable disease. Platinum-based chemotheraphy is still the cornerstone for the treatment of advanced NSCLC [4], with response rates of 25 to 35% and 1-year survival rate of about 30 to 40% [5]. However, platinum-based dual chemotherapy might result in frequent adverse effects and prevent completion of the recommended period of treatment, which finally may affect the therapeutic efficacy [6]. Therefore, there is a need to develop new strategies to maximize tumor control and minimize adverse effects in patients with advanced NSCLC.

In China, many patented Chinese medicines are used as adjunctive therapy and have gained popularity because of their potential effects in NSCLC patients [7–11]. Xiao-ai-ping injection (XAPI) which is extracted from Marsdenia Tenacissima Caulis, has been shown to have valid antitumor effects [12–15], including in lung cancer. The major bioactive compounds in XAPI are steroids, including tenacigenin A and tenacigenin B [16]. Modern pharmacological studies have demonstrated that XAPI, could enhance the gefitinib efficacy [17], and overcome erlotinib and gefitinib cross-resistance [18] in NSCLC patients.

Recently, many trials have reported that XAPI in combination with platinum-based chemotherapy is superior in improving objective tumor response, decreasing the severe adverse side effects, improving the quality of life and ameliorating symptoms in patients with advanced NSCLC. However, in some Chinese clinical trials, it is uncertain whether there is robust evidence on the efficacy and safety of XAPI as an adjuvant therapy to platinum-based chemotherapy. Thus, we conducted a comprehensive systematic review on the efficacy and safety of XAPI as an adjunctive therapy for advanced NSCLC.

Methods
Data resources and searching strategies
To explore the efficacy and safety of XAPI on patients with advanced NSCLC, relevant electronic data sources, including PubMed, EMBASE, the Cochrane Library, Chinese National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Database and Chinese Biology Medical
Ye L et al., 2017 [25] 30 30 NR IIIb-IV TP + XAPI (60 ml/d, d1–10) TP 1 ○○○○○○○○ 8
Hu XL et al., 2017 [26] 53 53 NR IIIb-IV GP + XAPI (20 ml/d, d1–15) GP 4 ○○○○○○○○ 9
Gu N et al., 2016 [27] 39 39 NR III-IV GP + XAPI (22 ml/d, d1–22) GP 1 ○ 7
Liu JR et al., 2016 [28] 30 30 ZPS ≤ 3 IIIb-IV GP + XAPI (40 ml/d, d1–14) GP 2 ○ 7
Li XG et al., 2016 [29] 64 58 KPS > 70 IIIb-IV GP + XAPI (80 ml/d, d1–8) GP 4 ○○○○ 7
Li QL et al., 2016 [30] 36 36 KPS > 70 IIIb-IV GP + XAPI (40–60 ml/d, d1–15) GP 2 ○○○○○○○○ 9
Gu N et al., 2015 [31] 53 53 KPS ≥ 61 IIIb-IV TP + XAPI (20 ml/d, d1–21) TP 2 ○○○○○ 7
Song Y et al., 2016 [32] 40 40 NR IIIb-IV GP/NP + XAPI (40 ml/d, d1–15) GP/NP 1 ○○○○○○○○ 8
Li YL et al., 2015 [33] 33 32 KPS ≥ 60 IIIb-IV TP + XAPI (60 ml/d, d1–15) TP 2 ○○○○○○○○ 8
Mei CR et al., 2015 [34] 30 33 KPS ≥ 60 IIIb-IV TP + XAPI (20 ml/d, d1–14) TP 2 ○○○○○○○○ 8
Shen LW et al., 2015 [35] 28 28 KPS ≥ 60 III-IV TP + XAPI (40–60 ml/d, d1–15) TP 2 ○○○○○○○○ 8
Ai L et al., 2015 [36] 33 32 KPS ≥ 60 IIIb-IV TP + XAPI (60 ml/d, d1–14) TP 2 ○○○○ 7
Shi L et al., 2015 [37] 26 26 NR IIIb-IV TP + XAPI (60 ml/d, d1–14) TP 3 ○ 7
Xia GA, 2013 [38] 39 39 KPS ≥ 50 IIIb-IV TP + XAPI (40 ml/d, d1–14) TP 2 ○○○○ 7
Yang WQ et al., 2013 [40] 43 43 KPS > 70 IIIb-IV GP + XAPI (4 ml/d, d1–8) GP 3 ○○○○○○○○ 9
Zhang FY et al., 2011 [41] 24 24 KPS ≥ 50 IIIb-IV GP + XAPI (40–60 ml/d, d1–15) GP 2 ○○○○○○○○ 8
Yang H et al., 2011 [42] 30 30 KPS ≥ 60 IIIb-IV NP + XAPI (60 ml/d, d1–7) NP 2 ○○○○ 7
Bai RL, 2010 [43] 36 36 KPS ≥ 60 IIb-IV NP + XAPI (60 ml/d, d1–15) NP 1 ○○○○ 7
Li J et al., 2009 [44] 38 38 KPS > 70 IIIb-IV GP + XAPI (40 ml/d, d1–15) GP 2 ○○○○○○○○ 8
Wang K et al., 2009 [45] 28 28 KPS > 50 IIIb-IV NP + XAPI (20–60 ml/d, d1–15) NP 2 ○○○○○○○○ 8
Wang WY et al., 2009 [46] 27 29 KPS ≥ 70 IIIb-IV TP + XAPI (80 ml/d, d1–7) TP 2 ○○○○ 7
Song CP, 2008 [47] 36 36 KPS ≥ 60 IIIb-IV NP + XAPI (60 ml/d, d1–15) NP 2 ○○○○ 7
Huang ZQ et al., 2007 [48] 30 32 KPS ≥ 50 IIIb-IV GP/TC/NP + XAPI (60 ml/d, d1–15) GP/TP/NP 2 ○○○○○○○○ 8

NR Not reported, DP Docetaxel plus Cisplatin, GP Gemcitabine plus Cisplatin, NP Navelbine plus Cisplatin, TP Taxol plus Cisplatin; outcomes: ORR; KPS; leukopenia; thrombocytopenia; anemia; nausea and vomiting; liver function; kidney function; diarrhea; constipation; fatigue; immune function.

Database (CBM) were searched for relevant articles from the date of their inception to December 2018. The language was restricted to Chinese and English. The search words were not limited to MeSH, and free words were also used as follows: (Neoplasm [Mesh] OR Lung Neoplasm [Mesh] OR Pulmonary Neoplasm OR Pulmonary Neoplasm OR Lung Cancer OR Thoracic Neoplasm OR Pulmonary Cancer OR Lung Carcinoma OR Pulmonary Carcinoma OR NSCLC OR Non-small Cell Lung Cancer) AND (Xiaoaiping OR Marsdenia tenacissima) extract). This research was conducted by two independent reviewers (FCF and ZCW), and any discrepancies were resolved either by discussion or by a third author (HLH).

Inclusion and exclusion criteria

Studies satisfying the following criteria were included: (1) Only clinical randomized controlled trials (RCTs); (2) Studies in which diagnosis of NSCLC had been verified by cytology or tissue biopsy. Furthermore, only patients with pathologically documented NSCLC of stage III or IV; according to the tumor-node-metastasis (TNM)-based staging of lung cancer were included; (3) studies where the treatment involved platinum-based chemotherapy with or without XAPI; and (4) Objective tumor response rate (ORR) and improvement of Karnofsky performance score (KPS) were regarded as the primary outcome measures. The adverse side effects and indicators of immune function were considered as secondary outcome measures.

All studies that did not meet the abovementioned inclusion criteria were excluded. In addition, studies were also excluded, if they were review articles, animal experiments, duplicated publications, inappropriate interventions, or they if did not present sufficient data.

Outcome measures

The primary outcomes included ORR and improvement of KPS. ORR was considered as an indicator of antitumor
effect and a surrogate for clinical benefit according to the Response Evaluation Criteria In Solid Tumors (RECIST) [19]. ORR was calculated by adding the complete response (CR) and partial response (PR). KPS was considered as an indicator of the quality of life in NSCLC patients after treatment [20]. An increase or decrease of 10-points in the KPS was regarded as an improvement or deterioration of quality of life, respectively. Hence, the improved performance status of patients was investigated and set as another primary outcome. In addition, secondary outcomes included reduction in grade 3/4 myelosuppression, nausea and vomiting, other adverse side effects (e.g. dysregulated liver and kidney function, diarrhea, constipation and fatigue), and immune function effects (the percentage of CD4+, CD8+, CD4+/CD8+).

Data extraction and quality assessment
Data were extracted by two independent reviewers (FCF and JRZ) and the divergences were resolved by discussion with the third expert adjudicator (HLH). From the eligible articles, the following data were collected, (1) basic information such as the name of the first author, publication year, and language; (2) patient demographics, including the number of patients, performance status, and TNM stage in each group; and (3) detailed interventions, duration of treatment, and outcomes.

The quality of the included studies was assessed according to the criteria in the Cochrane Handbook for the Systematic Reviews of Interventions (version 5.1.0) [21]. The seven aspects evaluated in the report were random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selecting reporting and other bias. Each aspect was categorized as a high, low, or uncertain risk. Furthermore, the quality of each trial was also assessed quantitatively with a scoring system from 0 to 14, which evaluated the following aspects including randomization, blinding, analysis, patient...
selection, comparability of groups at baseline, extent of follow-up, treatment protocol, cointerventions, and outcomes, as shown in Additional file 7: Table S1 [22]. This assessment strategy has been widely used in previous meta-analysis publications [23, 24]. Therefore, we adopted it in our study. The two independent reviewers (FCF and QW) performed the assessment and the disagreement was resolved by discussion or consulting the expert adjudicator (XMZ).

Subgroup analysis
Pre-specified subgroup analyses were performed to determine the potential causes of heterogeneity in the effects of XAPI on the primary outcomes. It was hypothesized that the treatment efficacy of XAPI was higher in trials using: i) a higher XAPI dose (≥ 60 ml per day) rather than lower dose usage; ii) a longer duration (> 14 days) rather than shorter duration, and iii) those with a low methodological quality (as studies with a higher methodological quality tend to exhibit more modest treatment effect).

Statistical analysis
Data were analyzed using RevMan 5.3. Pooled risk ratio (RR) and 95% confidence interval (95% CI) were used for statistical analysis of dichotomous variables, while statistical analysis for continuous variables was performed using mean difference (MD) and 95% CI. If the heterogeneity present in pooled studies (I²) was > 50% and/or \( P < 0.1 \), a random-effect model was used. Otherwise, a fix-effect model was applied. Outcomes were calculated using \( P \) values and \( P < 0.05 \) was considered statistically significant. Funnel plots were applied to evaluate the potential publication bias for primary outcomes if more than ten studies were included for a meta-analysis. Publication bias was further evaluated by Begg’s test using Stata 14.0 software.

Results
Data collection
Overall, 271 potentially relevant articles were identified from the seven databases in the initial search. After removing duplicated articles, the titles and abstracts of the
remaining 100 studies were screened, and 57 records were removed owing to inappropriate intervention (n = 19), animal or in vitro experiments (n = 25), review articles (n = 8), combination with herbs extracts other than XAPI (n = 3), and treatment for malignant pleural effusions (n = 2). Subsequently, the full-text of 43 articles were screened, and eight were excluded because of repeated data, retrospective nature of the study, incomplete raw data, and inappropriate control group. Finally, 24 were included in the meta-analysis after removing studies that did not provide detailed TNM stage. A flow diagram of the selection process is presented in Fig. 1.

Characteristics of the included studies

Twenty-four studies [25–48] published between 2007 and 2017, were included. These trials were all conducted in China. Overall 1725 patients with advanced NSCLC (863 who received XAPI in combination with platinum-based chemotherapy and 862 who received platinum-based chemotherapy alone) were identified and included in this meta-analysis. XAPI was administered intravenously, except in one study where it was administered intramuscularly [39]. The dosage of XAPI varied from 4 to 80 ml/d and the treatment duration ranged from one to four cycles. Among these researches, GP (Gemcitabine plus Cisplatin) [26–30, 39, 41, 44], TP (Taxol plus Cisplatin) [25, 31, 33–38, 46] and NP (Navelbine plus Cisplatin) [42, 43, 45, 47] regimens were the most common regimens. According to pathological TNM stages of NSCLC, all patients enrolled in the studies had stage III-IV disease. The demographic and clinical baseline characteristics of the included studies, such as the first
Methodological bias of the included studies

The risk of bias for each study was assessed according to the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0. All 24 studies declared the randomization, but only eleven [26–28, 30, 34–36, 39, 40, 44, 46] provided the details of the randomization process. Allocation concealment or blinding procedure was not mentioned. Only one study reported the drop-out data. No selective reporting bias was observed among all the trials. The presence of other bias was unclear. The detailed delineation of methodological quality of the included studies is summarized in Fig. 2. According to the score system we used in this meta-analysis, the mean methodologic score of the individual trials was 7.7 and median was 7.5 (range 7–9). The individual methodologic scores of each trial are available in Table 1.

Primary outcomes

Objective tumor response rate

ORR was reported in all 24 studies, for a total of 1725 patients [25–48]. As shown in Fig. 3, there was no significant heterogeneity ($I^2 = 0\%$, $p = 1.00$) among the
studies; thus, the fix-effect model was used to analyze the data. The results showed that the combination of XAPI and platinum-based chemotherapy significantly increased the number of patients who showed CR or PR, compared with platinum-based chemotherapy alone (RR: 1.27, 95% CI, 1.14–1.40, \( p < 0.00001 \)). In the subgroup analysis, the pooled RR showed significance in GP (RR: 1.17, 95% CI, 1.01–1.37, \( p = 0.04 \)) and TP (RR: 1.34, 95% CI, 1.13–1.60, \( p = 0.001 \)).

### Quality of life

As shown in Figs. 4, 16 of the 24 included studies [25, 27, 30, 33, 34, 36, 38, 40–48] had evaluated the changes in KPS. As there was no evidence of significant heterogeneity between the studies (\( I^2 = 18\% \), \( p = 0.24 \)), the fix-effect model was selected for analysis. The pooled analysis revealed that a significant difference (RR: 1.70, 95% CI, 1.48–1.95, \( p < 0.00001 \)) existed between the XAPI combination group and control group, suggesting XAPI combined with platinum-based chemotherapy could improve the quality of life. In the subgroup analysis, the pooled RR showed significance in GP (RR: 1.94, 95% CI, 1.38–2.72, \( P = 0.0001 \)), TP (RR: 1.39, 95% CI, 1.17–1.66, \( P = 0.0002 \)), NP (RR: 2.00, 95% CI, 1.48–2.70, \( P < 0.00001 \)) and other regimen (RR: 2.54, 95% CI, 1.37–4.69, \( P = 0.003 \)).

### Secondary outcomes

#### Reduction in grade 3/4 myelosuppression

The incidence of leukopenia, anemia and thrombocytopenia was reported in 15 trials [25, 26, 29–35, 39–41, 44, 45, 48], involving 1132 patients. The fix-effect model was used because of little heterogeneity (\( I^2 = 0\% \), \( p > 0.1 \)). Patients who received XAPI in combination with platinum-based chemotherapy had lesser occurrence of grade 3/4 leukopenia (RR: 0.49, 95% CI, 0.38–0.64, \( p < 0.00001 \); Fig. 5a), anemia (RR: 0.63, 95% CI, 0.46–0.87, \( p = 0.004 \); Fig. 5b) and thrombocytopenia (RR: 0.53, 95% CI, 0.38–0.73, \( p = 0.0001 \); Fig. 5c) than those who received platinum-based chemotherapy alone.

#### Reduction in grade 3/4 nausea and vomiting

The grade 3/4 nausea and vomiting were reported in nine trials [25, 30, 32–34, 39, 40, 44, 48], including 638 patients. The heterogeneity test showed a homogeneous group of studies (\( I^2 = 0\% \), \( p = 0.86 \)), and therefore, the fixed effect model was applied. The outcome revealed that XAPI could reduce the incidence of nausea and vomiting compared to the control group (RR: 0.57, 95% CI, 0.36–0.90, \( p = 0.02 \)), as shown in Fig. 6.

#### Other adverse side effects

Dysregulated liver and kidney function, diarrhea, constipation and fatigue were also reported in seven [25, 26, 30, 32–34, 39, 40, 44, 48], six [26, 30, 34, 40, 44, 48], five [26, 32, 33, 36, 44], four [26, 32, 33, 48] and three [31, 33, 35] trials, respectively. The fix-effect model was used due to little heterogeneity. The results showed that XAPI did not cause an increase in the dysregulated liver (RR: 0.90, 95% CI, 0.70–1.15, \( P = 0.40 \); Fig. 7a) and kidney function (RR: 0.70, 95% CI, 0.40–1.22, \( p = 0.21 \); Fig. 7b), diarrhea (RR: 0.86, 95% CI, 0.57–1.29, \( p = 0.46 \); Fig. 7c), constipation (RR: 0.96, 95% CI, 0.56–1.63, \( p = 0.87 \); Fig. 7d) and fatigue (RR: 1.04, 95% CI, 0.77–1.40, \( p = 0.80 \); Fig. 7e).

#### Immune function

Five trials [41, 43, 45, 46, 48], including 289 patients, reported the percentage of CD4+, CD8+, and CD4+/CD8+. Due to the high heterogeneity, the random-effect model was used to calculate the MD and 95% CI. Meta-analysis indicated that there was a statistically significant difference between the two groups for CD8+ (MD: 4.96, 95% CI, 1.16–8.76, \( p = 0.01 \); Fig. 8a) and CD4+/CD8+ (MD: 2.58, 95% CI, 1.69–3.47, \( p < 0.00001 \); Fig. 8b), but not for CD4+ (MD: 12.09, 95% CI, −0.34–24.52, \( p = 0.06 \).
Fig. 8c), which indicated that XAPI combined with chemotherapy could enhance the immune function in NSCLC patients to some extent.

**Subgroup analysis of ORR**

**Low vs. high dose of XAPI**

Among the 24 studies that evaluated the ORR, 13 studies [26–28, 31, 32, 34, 35, 38, 39, 41, 44, 45] and 11 studies [25, 29, 33, 36, 40, 42, 43, 46–48] reported the use of low (< 60 mg/d) and high (≥ 60 mg/d) dose of XAPI, respectively.

| Study or Subgroup | Experimental Events | Control Events | Total Events | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|---------------------|----------------|-------------|--------|-----------------------------|
| Low dose          |                     |                |             |        |                             |
| J Li et al, 2009  | 7 38               | 8 38           | 15 38       | 30.2%  | 0.68 (0.35, 1.37)           |
| QL Li et al, 2016 | 11 53             | 9 53           | 20 53       | 23.9%  | 0.65 (0.26, 1.61)           |
| Y Song, 2016      | 11 40             | 10 40          | 21 40       | 36.6%  | 0.79 (0.41, 1.52)           |
| Y Li et al, 2015  | 6 33              | 8 32           | 14 32       | 21.2%  | 0.73 (0.28, 1.86)           |
| Total (95% CI)    | 197                | 195            | 392         | 100.0% | 0.86 (0.57, 1.32)           |

**High dose**

| Study or Subgroup | Experimental Events | Control Events | Total Events | Weight | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|---------------------|----------------|-------------|--------|-----------------------------|
| J Li et al, 2009  | 6 33               | 9 32           | 15 32       | 23.9%  | 1.07 (0.42, 2.68)           |
| QL Li et al, 2016 | 5 33               | 6 32           | 11 32       | 21.2%  | 0.85 (0.25, 2.88)           |
| QL Huang et al, 2007 | 3 30         | 3 32           | 6 32        | 21.2%  | 0.85 (0.25, 2.88)           |
| Total (95% CI)    | 156                | 157            | 313         | 100.0% | 0.96 (0.56, 1.63)           |

**Short vs. long duration of treatment**

A total of ten studies [25, 28, 39, 40, 43–45, 47, 48] reported the administration of short (< 14 days in one treatment cycle) term (RR: 1.25, 95% CI, 1.08–1.46, p = 0.004) and long (> 14 days in one treatment cycle) term (RR: 1.28, 95% CI, 1.11–1.46, p = 0.0005) XAPI therapy.
Fig. 8 Forest plots showing comparison of immune function in Xiao-ai-ping injection plus chemotherapy and chemotherapy alone. 

- **a**: CD8+ T cell
- **b**: percentage of CD4+/CD8+
- **c**: CD4+ T cell

Fig. 9 Summary of subgroup analysis of effects of Xiao-ai-ping-injection (XAPI) on objective tumor response rate (ORR) in patients with advanced NSCLC

- Low dose (< 60 ml/d) — 1.32 (1.15, 1.53) P = 0.001
- High dose (≥ 60 ml/d) — 1.20 (1.04, 1.39) P = 0.01
- Subgroup difference P=0.35

- Short term (≤ 14 days) — 1.25 (1.08, 1.46) P = 0.004
- Long term (> 14 days) — 1.28 (1.11, 1.46) P = 0.0005
- Subgroup difference P=0.86

- High methodologic quality — 1.22 (1.04, 1.43) P = 0.02
- Low methodologic quality — 1.31 (1.15, 1.49) P < 0.0001
- Subgroup difference P=0.48

Fig. 9 Summary of subgroup analysis of effects of Xiao-ai-ping-injection (XAPI) on objective tumor response rate (ORR) in patients with advanced NSCLC.
No significant difference was found in the outcomes between the two groups, as shown in Fig. 9 and Additional file 2: Figure S2.

Effect of the study quality on the outcomes
The mean of the methodological score was 7.7 and this was regarded as the cut-off score for categorizing the studies into high-(> 7.7) and low-(< 7.7) quality subgroups. Among the 24 studies that evaluated the ORR, 13 [25, 26, 30, 32–35, 39–41, 44, 45, 48] were included in the high-quality subgroup, while 11 [27–29, 31, 36–38, 42, 43, 46, 47] were included in the low-quality subgroup. Although the treatment effects of XAPI did not show any significant difference between the two subgroups, low-methodological subgroup trials achieved a better outcome (RR: 1.27, 95% CI, 1.14–1.40, p < 0.0001) than the high-methodological subgroup (RR: 1.22, 95% CI, 1.04–1.43, p = 0.02). (Fig. 9 and Additional file 3: Figure S3).

Subgroup analysis of KPS
Low vs. high dose of XAPI
Among the 16 studies that evaluated the KPS, seven studies [27, 30, 34, 38, 41, 44, 45] and nine studies [25, 33, 36, 40, 42, 43, 46–48] reported the use of low (< 60 mg/d) and high (≥ 60 mg/d) dose of XAPI, respectively. The XAPI dose had no significant influence on the KPS (Fig. 10 and Additional file 4: Figure S4).

Short vs. long duration of treatment
A total of six studies [25, 34, 36, 40, 42, 46] and ten studies [27, 30, 33, 40, 41, 43–45, 47, 48] reported the administration of short (≤ 14 days in one treatment cycle) and long (> 14 days in one treatment cycle) term XAPI therapy. The duration of treatment did not influence the efficacy of XAPI significantly. However, the long-term subgroup showed a better outcome (RR: 1.91, 95% CI, 1.55–2.35, p < 0.0001) than the short-term subgroup (RR: 1.49, 95% CI, 1.25–1.79, p < 0.0001) (Fig. 10 and Additional file 5: Figure S5).

Effect of the study quality on the outcomes
The studies reporting on the KPS were also divided into a high-quality [25, 30, 33, 34, 40, 41, 44, 45, 48] and low-quality [27, 36, 38, 42, 43, 46, 47] subgroups, and no significant differences were observed between the two groups, as shown in Fig. 10 and Additional file 6: Figure S6.

Publication bias
To identify the publication bias among the eligible studies, funnel plots and Begg’s test were utilized. As shown in Fig. 11, the funnel plots were asymmetric for ORR and improved KPS, suggesting potential publication bias. Begg’s test further confirmed that publication bias did not exist, as the P value for objective tumor response and improvement of KPS were 0.843 and 0.087, respectively.

Discussion
In China, many patented Chinese medicines have been clinically integrated with standard chemotherapy in cancer patients for many years [49, 50]. However, their effectiveness is still a controversy worldwide due to the lack of systematic reviews summarizing the present evidence. Marsdenia tenacissima is known as “Tong-guan-Teng” or “Tong-guang-san” in Traditional Chinese Medicine (TCM) and its use was first recorded in ‘Dian Nan Ben Cao’ compiled by M-Lan dating back to Ming Dynasty. Its dried stems have been used for treating several kinds of diseases such as cancer, pneumonia, and tonsillitis. The extract of Marsdenia tenacissima has been available in China as a patented Chinese medicine named Xiao-ai-ping and is widely used for several cancers including NSCLC [51]. According to TCM, it is capable of relieving cough and asthma, eliminating phlegm, purging heat and has detoxifying effects. Modern pharmacology has identified polyoxypregnanes as the main effective ingredient, which can modulate P-glycoprotein and reverse multiple drug resistance in cancer [52]. XAPI could target apoptosis and autophagy leading to the death of NSCLC cells death [53]. Therefore, XAPI might enhance the efficacy of platinum-based chemotherapy. In addition, polysaccharide, another active ingredient of XAPI, can regulate the immune function and suppress tumor growth in mice [54]. Furthermore, XAPI can inhibit the migration of A549 cells [55], and serve as a potential anti-angiogenesis agent [56]. Taken together, XAPI might enhance the clinical efficacy of chemotherapeutic regimens by overcoming drug resistance, immunomodulation, and prevention of metastasis and tumor angiogenesis.

In the present meta-analysis, 1797 patients involved in 24 RCTs, were evaluated for the efficacy of XAPI in combination with platinum-based chemotherapy. The results of this meta-analysis showed that XAPI plus platinum-based chemotherapy was associated with better outcomes than platinum-based chemotherapy alone, as evidenced by higher ORR and improvement in KPS. In our subgroup analysis of different regimens, XAPI showed a relatively high ORR in the TP and GP regimens, which suggested that XAPI might play a synergistic effect in these subgroups. In addition, XAPI could improve the quality of life for NSCLC patients in all the subgroups, by increasing KPS. These results were encouraging and demonstrated that XAPI not only locally inhibit tumor growth but also improve the overall quality of life in NSCLC patients.
Adverse side effects are inevitable in most patients with advanced NSCLC receiving platinum-based chemotherapy, the severity of which can lead to treatment cessation in some cases. Myelosuppression and gastrointestinal reactions are the common platinum-based side effects. Study of the data showed, leukopenia, thrombocytopenia, anemia, nausea, and vomiting were the common grade 3/4 adverse side effects and our meta-analysis results revealed a significant reduction in their occurrence when XAPI was added to the platinum-based chemotherapy. Moreover, other side effects including dysregulated liver and kidney function, diarrhea, constipation, and fatigue, were also considered in this meta-analysis. The results showed that XAPI combined with chemotherapy did not increase the toxicity in the liver and kidney, which suggests that XAPI did not bring any metabolic burden to these organs. XAPI also did not cause more events in diarrhea, constipation, and fatigue, when combined with chemotherapy. Therefore, our results demonstrated that XAPI add-on platinum-based chemotherapy could decrease the platinum-based drugs induced severe myelosuppression and, nausea and vomiting but did not increase other side effects, supporting the efficacy and safety of XAPI.

In addition, immune function plays a vital role in lung cancer. Evidence showed that XAPI could improve the immune function to exert antitumor effects in mice [54]. Hence, the data associated with immune function were pooled into this meta-analysis to determine whether XAPI could potentiate the cellular immunity of advanced NSCLC patients. Though a small number of trials reported on these, the results revealed the percentages of CD8+ and...
CD4+/CD8+ cells were increased after treatment with XAPI, but not of CD4+ T cells. Collectively, these results illustrated that XAPI might exert anti-tumor effects by regulating immune function.

Furthermore, to address the potential heterogeneity in the primary outcomes, a hypothesis-based subgroup analysis of ORR was performed. The result showed that patients administrated with a low dose of XAPI exhibited better outcomes. It also suggested that doses under 60 ml/d might be the appropriate dose for NSCLC patients. The present meta-analysis also indicated that patients who received long duration treatment might have a higher ORR, though without significant subgroup difference ($p = 0.86$). Due to limitations in the methodological quality, subgroup analysis revealed better outcomes in studies with low methodological quality than those with high methodological quality. In the subgroup analysis of the KPS, the results were similar to ORR. We found that treatment dose and methodological quality did not influence the KPS. However, the results also demonstrated that advanced NSCLC patients who received long term treatment had a better outcome than those who received short term treatment. Collectively, this present meta-analysis demonstrated the efficacy of XAPI as an adjuvantive therapy for advanced NSCLC.

Of note, there were some shortcomings in this meta-analysis. First, all the included studies were susceptible to some bias due to following reasons: flaws in the methodology, since specific method and procedure of the trials were unclear or obscure; dropouts and withdrawals that could not be extracted from the trials; lack of description of the details of randomization and concealment of allocation and blinding, although all the trials referred to randomization; no information on whether the syndrome differentiation based on TCM theory was taken into consideration in diagnostic procedures. Hence, the selection bias, performance bias, and detection bias were likely to be present in this meta-analysis. Second, our results only exhibited the overall efficacy and adverse side effects of XAPI plus platinum-based chemotherapy when compared with platinum-based chemotherapy alone. However, XAPI related efficacy and adverse side effects could not be uncovered in NSCLC patients. Further, there was a lack of information on long-term follow-up to evaluate the efficacy and safety of XAPI. Third, all trials were conducted in China and published in Chinese. Therefore, whether it could be beneficial to a wide population is uncertain. Fourth, the results of our meta-analysis might be affected by various therapeutic dosages and durations of treatment. Finally, we did not contact the authors for detailed information and failed to search for unpublished trials. Altogether, due to the insufficient methodological quality of the included trials, the potential benefits of XAPI for NSCLC patients need to be further verified through high-quality RCTs with rigorous methodology and adequate assessment of the safety profiles of the interventions.

**Conclusions**

In summary, this meta-analysis suggested that XAPI in combination with platinum-based chemotherapy had a better tumor response, improved the quality of life, attenuated adverse side effects, and enhanced immune function in NSCLC patients. In addition, low dosage and long-term treatment of XAPI might be a choice for advanced NSCLC patients. However, the results should be interpreted with caution, due to possible methodological flaws. More well-designed trials with bigger sample sizes and multicenter studies are urgently warranted to confirm this conclusion.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s12906-019-2795-y.

**Additional file 1: Figure S1.** Subgroup analysis of effects of Xiao-ai-ping-injection (XAPI) on the objective tumor response rate (ORR) in patients with advanced NSCLC according to the different dosages of the analyzed studies.

**Additional file 2: Figure S2.** Subgroup analysis of effects of Xiao-ai-ping-injection (XAPI) on the Karnofsky Performance Status (KPS) in patients with advanced NSCLC according to the methodological quality of the analyzed studies.

**Additional file 3: Figure S3.** Subgroup analysis of effects of Xiao-ai-ping-injection (XAPI) on the objective tumor response rate (ORR) in patients with advanced NSCLC according to the treatment duration of the analyzed studies.

**Additional file 4: Figure S4.** Subgroup analysis of effects of Xiao-ai-ping-injection (XAPI) on the Karnofsky Performance Status (KPS) in patients with advanced NSCLC according to the different dosages of the analyzed studies.

**Additional file 5: Figure S5.** Subgroup analysis of effects of Xiao-ai-ping-injection (XAPI) on the Karnofsky Performance Status (KPS) in patients with advanced NSCLC according to the methodological quality of the analyzed studies.

**Additional file 6: Figure S6.** Subgroup analysis of effects of Xiao-ai-ping-injection (XAPI) on the Karnofsky Performance Status (KPS) in patients with advanced NSCLC according to the treatment duration of the analyzed studies.

**Additional file 7: Table S1.** Criteria used to assess methodological score.

**Abbreviations**

CBM: Chinese Biology Medical Database; CI: Confidence interval; CNKI: Chinese National Knowledge Infrastructure; KPS: Karnofsky performance score; MD: Mean difference; NSCLC: Non-small-cell lung cancer; ORR: Objective tumor response rate; RCTs: Randomized controlled trials; RECIEST: Response Evaluation Criteria In Solid Tumors; RR: Risk ratio; TNM: Tumor-node-metastasis; XAPI: Xiao-ai-ping injection

**Acknowledgements**

We would like to thank Editage [www.editage.cn] for English language editing.
The authors declare that they have no competing interests.

Competing interests
Not applicable.

Consent for publication
Not applicable.

Availability of data and materials
Specific study data are available from the authors on request.

Ethics approval and consent to participate
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, People's Republic of China.
2 Department of Respiratory Medicine, Jiangsu Province Hospital of Chinese Medicine, 155 Hanzhong Road, Nanjing 210029, People's Republic of China.
3 Department of Integrative Medicine and Neurobiology, State Key Laboratory of Medical Neurobiology, School of Basic Medical Sciences, Institutes of Brain Science, Brain Science Collaborative Innovation Center, Shanghai Medical College, Fudan University, Shanghai 200032, People's Republic of China.
4 Department of Physiology, Xu Zhou Medical University, Xu Zhou 221009, People's Republic of China.

Received: 23 July 2019 Accepted: 12 December 2019

Published online: 13 January 2020

References
1. Hirsch FR, Schildkott GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, Paz-Ares L. Lung cancer: current therapies and new targeted treatments. Lancet. 2007;369:301–11.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:59–87.
3. Planchar D, Popat S, Kerr K, Novello S, Smit EF, Falvey-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:192–237.
4. Nanna N, Johnson D, Temim S, Baker S Jr, Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jayeem SI, Leight R, Bely GI, Schiller JH, Schneider BJ, Smith TJ, Tabbah J, Biermann WA, Masters G. Systemic therapy for stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2017;35:3484–515.
5. Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small cell lung cancer. N Engl J Med. 2017;377:849–51.
6. Quoil E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavole A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansis E, Poudrenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Bennouna J, Tredaniel J, Ducolone A, Leibasby MP, Baudrin L, Laporte S, Millon B, Intergroupe Francophone de Cancérologie T. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378:1079–88.
7. Cao A, He H, Jing M, Yu B, Zhou X. Shenfu injection adjunct with platinum-based chemotherapy for the treatment of advanced non-small cell lung cancer: a meta-analysis and systematic review. Evid Based Complement Alternat Med. 2017;2017:758675.
8. Wang J, Li G, Yu L, Mo T, Wu Q, Zhou Z. Adi injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: a meta-analysis of 42 RCTs following the PRISMA guidelines. J Ethnopharmacol. 2018;221:137–50.
9. Duan B, Xie J, Rui Q, Zhang W, Xi Z. Effects of Shengmai injection add-on therapy to chemotherapy in patients with non-small cell lung cancer: a meta-analysis. Support Care Cancer. 2018;26:2103–11.
10. Yan Y, Gong Z, Xu Z. Commentary: Lico a causes ER stress and apoptosis via up-regulating miR-144-3p in human lung cancer cell line H292. Biom J. 2018;41:391–2.
11. Xu Z, Yan Y, Xiao DS, Zeng S, Qian L, Wang L, Yang X, Xiao Y, Gong Z. Radiosensitizing effect of diosmetin on radiosensitive lung cancer cells via Akt signaling pathway. PLoS One. 2017;12:e0175977.
12. Zhang D, Wu J, Wang K, Duan X, Liu S, Zhang B. Which are the best Chinese herbal injections combined with XELOX regimen for gastric cancer? A PRISMA-compliant network meta-analysis. Medicine. 2018;97:e10127.
13. Zheng AW, Chen YQ, Fang J, Zhang YL, Jia DD. Xiaoaiping injection combined with cisplatin can inhibit proliferation and invasion and induce cell cycle arrest and apoptosis in human ovarian cancer cell lines. Biomed Pharmacother. 2017;89:1172–7.
14. Fan W, Sun L, Zhou JQ, Zhang C, Qin S, Tang Y, Liu Y, Lin SS, Yuan ST. Marsdenia tenacissima extract induces G0/G1 cell cycle arrest in human esophageal carcinoma cells by inhibiting mitogen-activated protein kinase (MAPK) signaling pathway. Chin J Nat Med. 2015;13:428–37.
15. Huang Z, Wang Y, Chen J, Wang R, Chen Q. Effect of xiaoaiping injection on advanced hepatocellular carcinoma in patients. J Tradit Chin Med. 2013;33:34–8.
16. Han SY, Zhao MB, Zhuang GB, Li PP. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells. Lung Cancer. 2012;75:30–7.
17. Han SY, Zhao W, Sun H, Zhou N, Zhou F, An G, Li PP. Marsdenia tenacissima extract enhances gefitinib efficacy in non-small cell lung cancer xenografts. Phytomedicine. 2015;22:560–7.
18. Han SY, Zhao W, Han HB, Sun H, Xue D, Jiao YN, He XR, Jiang SL, Li PP. Marsdenia tenacissima extract overcomes Axl- and met-mediated erlotinib and gefitinib cross-resistance in non-small cell lung cancer cells. Onco target. 2017;8:98993–905.
19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, D'Amico TA,getRepository. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
20. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2:187–93.
21. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaborationhttp://www.cochrane.org/training/cochranehandbook. 2009.
22. Heyland DK, MacDonald S, Keefe L, Drover JW. Total parenteral nutrition in the critically ill patient: a meta-analysis. JAMA. 1998;280:2103–9.
23. Langlois PL, Manzanares W, Adhikari NKG, Lamontagne F, Stopeck C, Hill A, Heyland DK. Vitamin C administration to the critically ill: a systematic review and meta-analysis. J Parenter Enteral Nutr. 2019;43:335–46.
24. Manzanares W, Lemieux M, Elke G, Langlois PL, Bloos F, Heyland DK. High-dose intravenous selenium does not improve clinical outcomes in the critically ill: a systematic review and meta-analysis. Crit Care. 2016;20:356.
25. Ye L, Fu B. Efficacy of Xiaoaiping injection combined with docetaxel and cisplatinum for advanced non-small cell lung cancer. Shangrl Med J. 2017;46:1189–91 (In Chinese).
26. Hu XL, Liu XS. Clinical effect of Xiaoaiping injection combined with gemcitabine and carboplatin in treatment of IIIB and IV non-small cell lung cancer. Drug Eval Res. 2017;40:266–9 (In Chinese).
27. Gu N, Li ZG. Clinical observation of Xiaoaiping injection combined with chemotherapy in treatment with advanced non-small cell lung cancer. China Health Standard Manage. 2016;7:120–1 (In Chinese).
28. Liu JR, An YH, Yang WB, Zhao K. Clinical study on Xiaoaiping injection combined with GP regimen in the treatment of advanced lung squamous cell carcinoma. Chin J Tradit Chin. 2016;33:7 (In Chinese).
29. Li KG, Xing JJ. Clinical observation of Xiaoaiping injection combined with gemcitabine plus cisplatin for advanced non-small cell lung cancer patients. Chin J Clin. 2016;46:62–4 (In Chinese).
30. Li GL, Cheng B. Clinical effects of Xiaoaiping injection combined with GP chemotherapy regimen in treating patients with advanced non-small cell lung cancer. Chin Arch Tradit Chin Med. 2016;34:785–8 (In Chinese).
31. Yao J. Efficacy and safety of Xiaoaiping injection combined with chemotherapy for advanced non-small cell lung cancer. Modern J Integ Trad Chin Med. 2016;25:2706–8 (In Chinese).
32. Song Y, Qian XL, Wang SK, Chen ZP. Clinical efficacy evaluation of Xiaoaiping injection combined with chemotherapy in treating advanced non-small cell lung cancer. Clinical J Chin Med. 2016;8:122–5 (In Chinese).
33. Li YL, Zhou HG, Ni JZ, Liu LF, Cheng Y, Li LH. Clinical observation of Xiaoaiping injection combined with docetaxel plus carboplatin for advanced non-small cell lung cancer patients. Modern J Integr Tradit Chin Western Med. 2015;24:316–8 (In Chinese).
34. Mei CR, Wang K, Lei N, Mei ZI. Clinical observation of Xiaoaiping injection combined with TP regimen in the treatment of advanced non-small cell lung cancer. China Pharmacy. 2015;26:1513–3 (In Chinese).
35. Shen LW, Qiu WS, Lan CX, Yu XL, Du LL. Curative observation of Xiaoaiping injection combined with TP regimen in the treatment of patients with advanced non-small cell lung cancer. Chin Foreign Med Res. 2015;13:8–9 (In Chinese).
36. Ai L, Kou L, Yin H, Tang H, Chen HF. Efficacy of Xiaoaiping injection combined with docetaxel and carboplatin for advanced lung adenocarcinoma. Modern J Chin. 2015;17:39–41 (In Chinese).
37. Shi L, Yang WB, Bai YJ, Li N. Clinical observation of Xiaoaiping injection on advanced non-small cell lung cancer. Front Med. 2015;5:155–6 (In Chinese).
38. Xia GA. Effect of Xiaoaiping injection combined with TP regimen in the treatment of advanced non-small cell lung cancer. Proc Clin Med. 2013;22:83–5 (In Chinese).
39. Fang H, Wang J, Pan CF, Guo SG, Chu DJ, Zhang J. Xiaoaiping injection combined with cisplatin and gemcitabine for non-small cell lung cancer: a clinical observation. Eval Anal Drug-use Hosp China. 2013;13:165–8 (In Chinese).
40. Yang WD, Wang K. Xiaoaiping injection combined with intermittent chemotherapy for elderly patients with advanced non-small cell lung cancer. J Basic Clin Oncol. 2013;26:495–7 (In Chinese).
41. Zhang FY, Li QW, Guan JZ, Cui LP. Curative observation of Xiaoaiping injection combined with GP regimen in the treatment of patients with advanced non-small cell lung cancer. J Basic Clin Oncol. 2011;24:415–7 (In Chinese).
42. Yang H, Lu S, Wang J, Zhang CY. Effect of Xiaoaiping injection combined with NP regimen in the treatment of advanced non-small cell lung cancer. Chin Med Herald. 2011;8:64–5 (In Chinese).
43. Bai RL. Efficacy of Xiaoaiping injection combined with chemotherapy for advanced non-small cell lung cancer. Chin J Misdiagnos. 2010;10:5359–60 (In Chinese).
44. Li J, Zhang H. Clinical research of combined gemcitabine with Xiaoaiping injection on advanced non-small cell lung cancer: lower toxicity and higher efficacy. J Pract Oncol. 2009;23:307–10 (In Chinese).
45. Wang K, Guo ZX. Xiaoaiping injection combining with NP regimen in the treatment of 56 patients with advanced lung cancer. J Basic Clin Oncol. 2009;22:47–8 (In Chinese).
46. Wang WY, Zhou Y, Zhang XJ, Gao TH, Luo ZF, Liu MY. A random study of xiaoaiping injection combined with chemotherapy on the treatment of advanced non-small cell lung cancer. J Basic Clin Oncol. 2009;14:936–8 (In Chinese).
47. Song CP. Clinical observation of Xiaoaiping injection combined with chemotherapy for 36 cases of advanced non-small cell lung cancer patients. J Tradit Chin Med. 2008;49:494 (In Chinese).
48. Huang ZQ, Tan H, Wang CY, Zhang HZ, Liu O, Zhou CZ, Liu X. Clinical research of combined xiaoaiping injection with chemotherapy on advanced non-small cell lung cancer. Chin Clin Oncol. 2007;12:97–102 (In Chinese).
49. Chen X, Xu Z, Zeng S, Wang X, Liu W, Qian L, Wei J, Yang X, Shen Q, Gong Z, Yan Y. The molecular aspect of antitumor effects of protease inhibitor nafamostat mesylate and its role in potential clinical applications. Front Oncol. 2019;9:952.
50. Wei J, Yan Y, Chen X, Qian L, Zeng S, Li Z, Dai S, Gong Z, Xu Z. The roles of plant-derived triptolide on non-small cell lung cancer. Oncol Res. 2019;27:849–59.
51. Wang X, Yan Y, Chen X, Zeng S, Qian L, Ren X, Wei J, Yang X, Zhou Y, Gong Z, Xu Z. The antitumor activities of Marsdenia tenacissima. Front Oncol. 2018;8:473.
52. To KW, Wu X, Yin C, Chai S, Yao S, Kadioglu O, Effert T, Ye Y, Lin G. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polysycopyranegens. J Ethnopharmacol. 2017;203:110–9.
53. Jiao YN, Wu LN, Xue D, Liu XJ, Tian ZH, Jiang ST, Han SY, Li PP. Marsdenia tenacissima extract induces apoptosis and suppresses autophagy through ERK activation in lung cancer cells. Cancer Cell Int. 2018;18:149.
54. Wang Y, Cheng B, Wang Z, Zhang W, Hao K, Chen Y, Li K, Wang T, Xie Y, Huang Z, Tong X. Marsdenia tenacissima extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement. Oncotarget. 2016;7:82851–63.
55. Lin SS, Li FF, Sun L, Fan W, Gu M, Zhang LY, Qin S, Yuan ST. Marsdenia tenacissima extract suppresses A549 cell migration through regulation of CCR5-CCL5 axis, rho C, and phosphorylated FAK. Chin J Nat Med. 2016;14:203–9.
56. Huang Z, Lin H, Wang Y, Cao Z, Lin W, Chen Q. Studies on the anti-angiogenic effect of Marsdenia tenacissima extract in vitro and in vivo. Oncol Lett. 2013;5:917–22.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.